皮下曲前列尼尔治疗严重不可手术慢性血栓栓塞性肺动脉高压(CTREPH):双盲3期随机对照试验
本研究为24周随机双盲对照试验,纳入105例不可手术或肺动脉内膜切除术后持续/复发性肺动脉高压的CTEPH患者,比较皮下高剂量与低剂量曲前列尼尔。
要点
- 皮下高剂量曲前列尼尔可显著改善严重CTEPH患者第24周6分钟步行距离。
- 高剂量与低剂量组严重不良事件发生率相似,常见为输注部位疼痛和反应。
- 皮下曲前列尼尔为WHO功能III或IV级CTEPH患者提供胃肠外治疗选择。
核心结论
- 皮下曲前列尼尔治疗严重CTEPH安全,并改善运动能力。
研究设计与样本
- 24周随机双盲对照试验,纳入105例不可手术或肺动脉内膜切除术后持续/复发性肺动脉高压的CTEPH患者,1:1分配至高剂量或低剂量皮下曲前列尼尔。
主要发现
- 低剂量组52例中10例(19%)报告12起严重不良事件,高剂量组53例中9例(17%)报告16起严重不良事件。
- 两组最常见治疗相关不良事件为输注部位疼痛和其他输注部位反应。
关键数值与推荐
- 高剂量组目标剂量约为30 ng/kg每min(第12周),低剂量组目标剂量约为3 ng/kg每min(第12周)。
- 纳入标准包括WHO功能III或IV级且6分钟步行距离150-400米。
临床怎么用
- 皮下曲前列尼尔可作为WHO功能III或IV级严重CTEPH患者的胃肠外治疗选择,尤其适用于不能耐受其他治疗或需要联合治疗者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treprostinil, a prostacyclin analogue, is effective for the treatment of pulmonary arterial hypertension. However, information is scarce regarding treprostinil for treatment of chronic thromboembolic pulmonary hypertension (CTEPH). The aim of this study was to examine the efficacy and safety of subcutaneous treprostinil in this setting. METHODS: In this 24-week, randomised, double-blind controlled trial, we enrolled patients with CTEPH, classified as non-operable, or with persistent or recurrent pulmonary hypertension after pulmonary endarterectomy, in six European expert centres in Austria, Czech Republic, Germany, and Poland. Patients in WHO functional class III or IV with a 6-min walk distance of 150-400 m were randomly assigned at a 1:1 allocation ratio to continuous high-dose subcutaneous treprostinil (target dose around 30 ng/kg per min at week 12) or low-dose subcutaneous treprostinil (target dose around 3 ng/kg per min at week 12). The primary endpoint was the change from baseline in 6-min walk distance at week 24. All patients who received at least one dose of the study drug were included in the intention-to-treat efficacy and safety analyses based on assessment of adverse events. The trial was registered at ClinicalTrialsRegister.eu EudraCT number 2008-006441-10 and ClinicalTrials.gov, number NCT01416636. FINDINGS: From March 9, 2009, to June 9, 2016, 105 patients were enrolled with 53 (50%) patients randomly assigned to high-dose and 52 (50%) patients to low-dose subcutaneous treprostinil. At week 24, marginal mean 6-min walk distance improved by 44·98 m (95% CI 27·52 to 62·45) in the high-dose group, and by 4·29 m (95% CI -13·34 to 21·92) in the low-dose group (treatment effect 40·69 m, 95% CI 15·86 to 65·53, p=0·0016). 12 serious adverse events were reported in ten (19%) of 52 patients from the low-dose group and 16 serious adverse events were reported in nine (17%) of 53 patients from the high-dose group. The most common treatment-related adverse events in both groups were infusion site pain and other infusion site reactions. INTERPRETATION: Treatment with subcutaneous treprostinil was safe, and improved exercise capacity in patients with severe CTEPH. Subcutaneous treprostinil provides a parenteral treatment option for patients of WHO functional class III or IV and those who do not tolerate other therapies or need combination treatment. FUNDING: SciPharm Sàrl.
引用
- Sadushi-Kolici R, Jansa P, Kopec G, et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med. 2018. PMID: 30477763. doi:10.1016/S2213-2600(18)30367-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。